

TEXAS

Case Number: 2:07-CV-139(TJW)

* Include a notation as to the location of any exhibit not held with the case file or not available because of size

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF TEXAS

CENTOCOR ORTHO BIOTECH, INC. AND
NEW YORK UNIVERSITY
Plaintiff,

Civil Action No. 2:07CV139

v.

ABBOTT LABORATORIES,
ABBOTT BIORESEARCH CENTER, INC. AND
ABBOTT BIOTECHNOLOGY, LTD.
Defendant.

§ § § § § § § § § §

PLAINTIFFS' TRIAL EXHIBIT LIST
DRAFT OF JUNE 22, 2009

Presiding Judge:	Plaintiff's Attorney(s):	Defendant's Attorney(s):
Hon. T. John Ward	WOODCOCK WASHBURN LLP	WILMERHALE
Trial Date:	Court Reporter:	Courtroom Deputy:
June 22, 2009	Susan Simmons	

All pre-admitted exhibits were received and admitted on 6/22/09.

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 1	CERTIFIED COPY OF U.S. PATENT 7,070,775 ISSUED TO LE ET AL. ENTITLED, "RECOMBINANT A2-SPECIFIC TNF α SPECIFIC ANTIBODIES." (MARKS, 10/21/08)					X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 2	CERTIFIED COPY OF U.S. PATENT 7,276,239 ISSUED TO LE ET AL. ENTITLED, "RECOMBINANT A2-SPECIFIC TNF α SPECIFIC ANTIBODIES," (MARKS, 10/21/08)					X		06/12/09
PX 3	JOHNSON & JOHNSON CREDO.				R, D, F			
PX 4	US PATENT APPLICATION PUBLICATION US 2004/0166111 ISSUED TO KAYMAKALAN ET AL. ENTITLED, "LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFALPHA ACTIVITY IS DETRIMENTAL."				R, D, F			
PX 5	CERTIFIED COPY OF FILE HISTORY FOR 07/670,827.	ABT01361937-1362085				X		06/12/09
PX 6	CERTIFIED COPY OF FILE HISTORY FOR 07/853,606.	ABT01362086-1362241				X		06/12/09
PX 7	CERTIFIED COPY OF FILE HISTORY FOR 08/013,413.	ABT01362778-1362999				X		06/12/09
PX 8	CERTIFIED COPY OF FILE HISTORY FOR 08/010,406.	ABT01362460-1362776				X		06/12/09
PX 9	CERTIFIED COPY OF FILE HISTORY FOR U.S. PATENT 5,919,452.	ABT01364745-1365669				X		06/12/09
PX 10	CERTIFIED COPY OF FILE HISTORY FOR 08/570,674.	ABT01366639-1367209				X		06/12/09
PX 11	CERTIFIED COPY OF FILE HISTORY FOR U.S. PATENT 5,656,272.	ABT01363978-1364744				X		06/12/09
PX 12	CERTIFIED COPY OF FILE HISTORY FOR U.S. PATENT 6,284,471.	ABT01363000-1363977				X		06/12/09
PX 13	CERTIFIED COPY OF FILE HISTORY FOR U.S. PATENT 5,698,195.	ABT01365670-1366638				X		06/12/09
PX 14	CERTIFIED COPY OF FILE HISTORY FOR U.S. PATENT 6,277,969.	ABT01367210-1367867				X		06/12/09
PX 15	CERTIFIED COPY OF FILE HISTORY FOR U.S. PATENT 6,835,823.	ABT01367868-1371010				X		06/12/09
PX 16	CERTIFIED COPY OF FILE HISTORY FOR U.S. PATENT 7,276,239.	CCOR00019962-21061				X		06/12/09
PX 17	CERTIFIED COPY OF APPLICATION 07/670,827.	ABT01361937-1362044				X		06/12/09
PX 18	CERTIFIED COPY OF APPLICATION 08/192,861.	ABT01364745-1364952				X		06/12/09
PX 19	CERTIFIED COPY OF APPLICATION 08/192,093.	ABT01363000-1363181				X		06/12/09
PX 20	CERTIFIED COPY OF APPLICATION 08/010,406.	ABT01362460-1362522				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 21	CERTIFIED COPY OF APPLICATION 07/853,606.	ABT01362086-1362197				X		06/12/09
PX 22	CERTIFIED COPY OF APPLICATION 07/943,852.	ABT01362242-1362381				X		06/12/09
PX 23	CERTIFIED COPY OF APPLICATION 08/013,413.	ABT01362778-1362909				X		06/12/09
PX 24	CERTIFIED COPY OF APPLICATION 08/192,102.	ABT01363978-1364187				X		06/12/09
PX 25	ABBOTT EUROPEAN HUMIRA LABEL.	ABBOTT-ARB2 04046-4234			R, A			
PX 26	CURRICULUM VITAE OF JAMES D. MARKS, M.D., Ph.D. DATED 11/01/07. (MARKS, 10/21/08)					X		06/12/09
PX 27	EXCERPTS FROM SCIENCE, 4 NOVEMBER 2005, VOL. 310, NO. 574, PAGE 761. (MARKS, 10/21/08)				R, I			
PX 28	JOINT CLAIM CONSTRUCTION AND PREHEARING STATEMENT DATED 09/26/08. (MARKS, 10/21/08)				F, O, R			
PX 29	DEFENDANTS' EXHIBIT B TO DEFENDANT'S CLAIM CONSTRUCTION AND EXTRINSIC/INTRINSIC EVIDENCE WITH HANDWRITTEN NOTATIONS. (MARKS, 10/21/08)				F, O, R, M			
PX 30	PLAINTIFFS' EXHIBIT A TO JOINT CLAIM CONSTRUCTION AND PREHEARING STATEMENT DATED 09/26/08 WITH HANDWRITTEN NOTATIONS. (MARKS, 10/21/08)				F, O, R, M			
PX 31	CHAPTER 1 FROM "ANTIBODIES - A LABORATORY MANUAL" AUTHORED BY HARLOW AND LANE. (MARKS, 10/21/08)				I			
PX 32	DOCUMENTS CITED IN EXHIBIT B - SEPTEMBER 2008 ABBOTT/CENTOCOR JOINT FILING REGARDING CLAIM CONSTRUCTION. (MARKS, 10/21/08)				F, O, R, M			
PX 33	HANDWRITTEN NOTES BY MARKS MADE AT 10/21/08 DEPOSITION. (MARKS, 10/21/08)				R			
PX 34	CERTIFIED COPY OF U.S. PATENT 7,070,775 ISSUED TO LE ET AL. ENTITLED, "RECOMBINANT A2-SPECIFIC TNF α SPECIFIC ANTIBODIES." (MARKS, 10/21/08)							

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 35	DOCUMENTS CITED IN EXHIBIT A - SEPTEMBER 2008 ABBOTT/CENTOCOR JOINT FILING REGARDING CLAIM CONSTRUCTION. (MARKS, 10/21/08)				F, O, R, M			
PX 36	BLACK BINDER CONTAINING COPIES OF '775 AND '239 PATENTS. (MARKS, 10/21/08)				M			
PX 37	01/25/99 LETTER FROM HOLVECK TO MYERS, RUBIN AND SCODARI RELATING TO CENTOCOR BEING SELECTED AS HONOREE FOR NORD'S 1999 CORPORATE AWARD FOR THE DEVELOPMENT OF THE ORPHAN DRUG REMICADE FOR THE TREATMENT OF CROHN'S DISEASE.	CCOR00039922			R, H			
PX 38	02/05/08 LETTER FROM MARTIN TO SCHOLZ REGARDING INQUIRY ABOUT THE BASIS FOR ABBOTT'S BELIEF THAT THE LAWSUIT CENTOCOR/NYU HAVE FILED AGAINST ABBOTT IN THE E.D. TEXAS IMPLICATES THE REIMBURSEMENT PROVISIONS UNDER SECTION 15.1 OF THE PURCHASE AGREEMENT BETWEEN ABBOTT AND BASF DATED 12/14/00.	ABT00424134-424152			R, P			
PX 39	01/03/03 EMAIL STRING FROM VERNON TO MCGINN AND BIERLY REGARDING ABBOTT AND LICENSING ISSUES.	CCOR01698260-1698262			H, R			
PX 40	12/13/05 EMAIL STRING FROM DOW TO JOHNSON AND PLANTZ REGARDING ISSUE FEE PAID FOR US SERIAL NO. 10/198,845.	CCOR01791381-1791384			H, FRE 408, P			
PX 41	03/13/06 EMAIL STRING FROM DOW TO SCODARI, HEYMAN, JOHNSON, MCGINN, JOHNSON, MCHUGH, SIEGEL, ANDERSON, DICHTER, TOWNSEND, PLANTZ AND FISCHER REGARDING PROJECT AUGUST.	CCOR01791389-1791390			H, O, FRE 408, P			
PX 42	03/13/06 EMAIL STRING FROM DOW TO JOHNSON REGARDING PROJECT AUGUST.	CCOR01791391-1791392			H, O, F, FRE 408, P			
PX 43	04/16/06 EMAIL STRING FROM SCODARI TO HEYMAN, POON, JOHNSON, JOHNSON AND FISCHER REGARDING LICENSING ISSUES.	CCOR01791393-1791394			H, O, F, FRE408, P			
PX 44	07/31/06 EMAIL FROM HEYMAN TO SCODARI, PETERSON, MCGINN AND DOW REGARDING PROJECT AUGUST.	CCOR01707888			H, F, FRE 408, P			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 45	01/10/07 EMAIL FROM HEYMAN TO SCODARI, PETERSON, FOWLER, MCGINN, DOW AND BRAUNREUTHER REGARDING ABBOTT IL 12.	CCOR01707891			H, F, FRE 408, P			
PX 46	03/05/07 EMAIL STRING FROM HEYMAN TO JOHNSON AND SCODARI REGARDING CONNOR PATENTS/ABBOTT.	CCOR01791395-1791398			H, FRE 408, P			
PX 47	04/16/07 EMAIL STRING FROM JOHNSON TO SCODARI, HARRIS, DEYO, BRAUNREUTHER, VANITALLIE, DOW, HEYMAN, VALERIANI, POON AND PETERSON REGARDING ABBOTT.	CCOR01791399-1791400			H, F, FRE 408, O, P			
PX 48	ARTICLE BY VANDEVENTER ET AL. ENTITLED, "TUMOUR-NECROSIS-FACTOR ANTIBODY TREATMENT IN CROHN'S DISEASE," PUBLISHED IN THE LANCET, VOL. 342, JULY 17, 1993.	CCOR00039080-39081			R	X		06/12/09
PX 49	05/17/07 DECLARATION OF ANDREW PAUL COPE IN PATENTEE'S RESPONSE TO OPPOSITION – EP-B-0 914 157: KENNEDY INSTITUTE OF RHEUMATOLOGY.				O, H, F, R			
PX 50	09/29/08 LETTER FROM MARTIN REGARDING PATENTEE'S RESPONSE TO OPPONENT OV'S SUBMISSIONS OF 01/28/08.				O, R, H, F			
PX 51	CENTOCOR'S NOTICE OF DEPOSITION PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 30(b)(6) DATED 11/05/08. (SALFELD, 01/23/09)					X		06/12/09
PX 52	U.S. PATENT 6,090,382 ISSUED TO SALFELD ET AL. ENTITLED, "HUMAN ANTIBODIES THAT BIND HUMAN TNFα." (SALFELD, 01/23/09)					X		06/12/09
PX 53	U.S. PATENT 7,223,394 ISSUED TO SALFELD ET AL. ENTITLED, "HUMAN ANTIBODIES THAT BIND HUMAN TNFα." (SALFELD, 01/23/09)					X		06/12/09
PX 54	U.S. PATENT 6,509,015 ISSUED TO SALFELD ET AL. ENTITLED, "HUMAN ANTIBODIES THAT BIND HUMAN TNFα." (SALFELD, 01/23/09)					X		06/12/09
PX 55	U.S. PATENT 6,258,562 ISSUED TO SALFELD ET AL. ENTITLED, "HUMAN ANTIBODIES THAT BIND HUMAN TNFα." (SALFELD, 01/23/09)					X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 56	U.S. PATENT APPLICATION PUBLICATION US/2006/0024293 A1 ISSUED TO SALFELD ET AL. ENTITLED, "HUMAN ANTIBODIES THAT BIND HUMAN TNF α ." (SALFELD, 01/23/09)					X		06/12/09
PX 57	U.S. PATENT APPLICATION PUBLICATION US/2007/0249813 A1 ISSUED TO SALFELD ET AL. ENTITLED, "HUMAN ANTIBODIES THAT BIND HUMAN TNF α ." (SALFELD, 01/23/09)					X		06/12/09
PX 58	ABSTRACT REPRODUCTION FORM FOR ABSTRACT ENTITLED, "RAISED SERUM LEVELS OF TUMOUR NECROSIS FACTOR IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME" AUTHORED BY THOELKEN, MOLLER, GMEIN, KOMMERELL AND THELLMAN. (SALFELD, 01/23/09)	ABT01374921						
PX 59	PUBMED SEARCH RESULT FOR ABSTRACT ENTITLED, "IMMUNOMODULATING CYTOKINES IN ATOPIC DERMATITIS AND PSORIASIS: PRODUCTION OF TUMOUR NECROSIS FACTOR AND LYMPHOTOXIN BY MONONUCLEAR CELLS IN VITRO." (SALFELD, 01/23/09)	ABT01374922						
PX 60	04/13/88 LETTER FROM SIEBECK TO MOLLER REGARDING SAMPLES. (SALFELD, 01/23/09)	ABT01374923			FL			
PX 61	EXCERPT FROM BONE MARROW TRANSPLANTATION (1991), 8, 93-98 ENTITLED, "TREATMENT OF AGVHD WITH OKT3: CLINICAL OUTCOME AND SIDE-EFFECTS ASSOCIATED WITH RELEASE OF TNF α " AUTHORED BY GLEIXNER ET AL. (SALFELD, 01/23/09)	ABT01374924			I			
PX 62	EXCERPT FROM LYMPHOKINE AND CYTOKINE RESEARCH, VOLUME 10, NUMBER 1, 1991 ENTITLED, "EVALUATION OF MEASUREMENT OF HUMAN TNF IN PLASMA BY ELISA" AUTHORED BY ENGLEBERTS, ET AL. (SALFELD, 01/23/09)	ABT01374925			I			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 63	EXCERPT FROM JOURNAL OF HEPATOLOGY, 1992, 15: 129-135 ENTITLED, "T LYMPHOCYTES FROM PATIENTS WITH PRIMARY BILIARY CIRRHOSIS PRODUCE REDUCED AMOUNTS OF LYMPHOTOXIN, TUMOR NECROSIS FACTOR AND INTERFERON- γ UPON MITOGEN STIMULATION" AUTHORED BY SPENGLER ET AL. (SALFELD, 01/23/09)	ABT01374926			I			
PX 64	11/19/87 LETTER FROM HYERS TO MOLLER REGARDING REQUEST FOR MOAB195 AND MOAB199. (SALFELD, 01/23/09)	ABT01374927			F, R, H			
PX 65	APPLICATION FOR EXTENSION OF PATENT TERM FOR US PATENT 6,090,382 ISSUED TO SALFELD. (SALFELD, 01/23/09)	ABT00033385			F, R, H			
PX 66	PRESCRIBING INFORMATION FOR HUMIRA. (SALFELD, 01/23/09)	CCOR00390800-390826				X		06/12/09
PX 67	12/08/02 EMAIL FROM SAKORAFAS TO KAYMAKALAN REGARDING COMPLETE BIACORE AFFINITY AND EPI TOPE MAPPING USING PEPTIDE MAB'S, SEGARD, D2E7 AND REMICADE. (SALFELD, 01/23/09)	ABT00161671			R, F, P			
PX 68	CHART REFLECTING BIACORE MEASUREMENTS FOR THE INTERACTION BETWEEN CAPTURED ANTIBODY AND SOLUBLE RHTNF α . (SALFELD, 01/23/09)	ABT00161672-161679			R, F, P			
PX 69	REPORT REFLECTING DETERMINATION OF THE EQUILIBRIUM DISSOCIATION CONSTANT FOR IGG1 D2E7 BY ANTIBODY CAPTURE ASSAY. (SALFELD, 01/23/09)	ABT00395922-395927				X		06/12/09
PX 70	PRESENTATION ENTITLED, "ETANERCEPT, INFliximab AND ADALIMUMAB BIND TO SOLUBLE AND TRANSMEMBRANE TNF WITH SIMILAR AFFINITIES" AUTHORED BY KAYMAKALAN, SAKORAFAS AND BOSE. (SALFELD, 01/23/09)	ABT00322168-322186				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 71	BIOLOGIC LICENSE APPLICATION (BLA) FOR HUMIRA DATED 10/08/97. (SALFELD, 01/23/09)	ABT00016041-16503				X		06/12/09
PX 72	05/02/07 EMAIL FROM ARGIRIADI TO SALFELD, TALANIAN AND BANACH REGARDING INTERFACE RESIDUES ON TNF. (SALFELD, 01/23/09)	ABT00049125-49127				X		06/12/09
PX 73	07/22/91 RESEARCH PROPOSAL: DEVELOPMENT OF A SECOND GENERATION PRODUCT WHICH NEUTRALIZES THE ACTIVITY OF TNF α BY LI, MANKOVICH, MOLLER, SALFELD AND WONG. (SALFELD, 01/23/09)	ABT00086643-86660				X		06/12/09
PX 74	10/01/92 MEMO FROM MANKOVICH, SALFELD AND TRACEY TO SCHOLLMEIER, KAMEN AND MOELLER REGARDING CAT PROPOSAL. (SALFELD, 01/23/09)	ABT00078908-78910				X		06/12/09
PX 75	09/25/93 REPORT ON THE ISOLATION OF HUMAN ANTIBODIES WITH HIGH AFFINITY FOR AND NEUTRALIZING ACTIVITY AGAINST HUMAN TNF α AUTHORED BY HOOGENBOOM, ROBERTS AND ALLEN. (SALFELD, 01/23/09)	ABT00086577-86610				X		06/12/09
PX 76	CHART ILLUSTRATING THE OVERVIEW OF THE RELATIONSHIP OF THE "PATENTS" AND THIRD PARTY PATENTS TO THE PROCESS USED TO PRODUCE HUMIRA. (SALFELD, 01/23/09)	ABT00086611-86612			F, R, O			
PX 77	12/20/93 REPORT ON THE ISOLATION OF HUMAN ANTIBODIES WITH HIGH AFFINITY FOR AND NEUTRALIZING ACTIVITY AGAINST HUMAN TNF α AUTHORED BY HOOGENBOOM, ALLEN AND ROBERTS. (SALFELD, 01/23/09)	ABT00086623-86642				X		06/12/09
PX 78	09/27/92 REPORT ON COMPARISON OF THE CAT AND GENPHARM APPROACHES TO HUMAN ANTIBODIES UNDER SPECIAL CONSIDERATION OF THE TNF- α PROJECT BY SALFELD. (SALFELD, 01/23/09)	ABT00194994-19497				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 79	03/12/93 MEMO FROM TRACEY TO DAUM, KAUL, KEMPENI, SPIGELMAN, KAMEN, MCRAE, MOELLER AND SALFELD REGARDING ANTI-TNF EFFECTS IN RHEUMATOID ARTHRITIS. (SALFELD, 01/23/09)	ABT00194924-194925			H, P			
PX 80	01/94 OVERVIEW - HUMAN ANTI-TNF α ANTIBODIES. (SALFELD, 01/23/09)	ABT00194770-194776				X		06/12/09
PX 81	ARTICLE - PROMISE FOR ANTI-TNF IN RHEUMATOID ARTHRITIS AND CROHN'S DISEASE. (SALFELD, 01/23/09)	ABT00194826-194828			F, H, A, I			
PX 82	CENTOCOR'S NOTICE OF DEPOSITION PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 30(b)(6) DATED 11/05/08. (LUBBERT, 02/06/09)					X		06/12/09
PX 83	02/03/09 LETTER FROM VERRECCHIO TO MAJOR REGARDING DESIGNATION OF WITNESSES FOR DEPOSITIONS. (LUBBERT, 02/06/09)					X		06/12/09
PX 84	02/03/09 EMAIL FROM MAJOR TO VERRECCHIO REGARDING DESIGNATION OF CHERYL LUBBERT AS ABBOTT'S REPRESENTATIVE ON TOPIC 3 OF 30(B)(6) NOTICE. (LUBBERT, 02/06/09)					X		06/12/09
PX 85	FLOWCHART REFLECTING LEGAL ENTITY FLOW OF HUMIRA AP (ADALIMUMAB) MANUFACTURED FOR COMMERCIAL SALE OR COMMERCIAL USE. (LUBBERT, 02/06/09)	ABT00316973				X		06/12/09
PX 86	LIST OF INTERNATIONAL ABBOTT ENTITIES INVOLVED IN SALES OR DISTRIBUTION OF HUMIRA. (LUBBERT, 02/06/09)	ABT00316972			F, A, R			
PX 87	08/2006 HUMIRA MARKET RESEARCH MONTHLY REPORT. (LUBBERT, 02/06/09)	ABT00633528-633576			F	X		06/12/09
PX 88	05/2008 HUMIRA MARKET RESEARCH MONTHLY REPORT. (LUBBERT, 02/06/09)	ABT00820420-820466				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 89	03/2007 HUMIRA MARKET RESEARCH MONTHLY REPORT. (LUBBERT, 02/06/09)	ABT00595754-595782				X		06/12/09
PX 90	12/2002 HUMIRA MARKET RESEARCH MONTHLY REPORT. (LUBBERT, 02/06/09)	ABT00631812-631832				X		06/12/09
PX 91	LIST OF INDIVIDUALS CONSULTED DURING PREPARATION OF CHERYL LUBBERT. (LUBBERT, 02/06/09)				Exhibit does not match description	X		06/12/09
PX 94	2006 HUMIRA PROFESSIONAL MARKETING PLAN. (LUBBERT, 02/06/09)	ABT00430384-430466			F	X		06/12/09
PX 95	04/05/07 HUMIRA COMPETITIVE SIMULATION FINAL REPORT. (LUBBERT, 02/06/09)	ABT00440577-440693				X		06/12/09
PX 96	SELF-INJECTABLE AND INFUSED BIOLOGIC AGENTS. (LUBBERT, 02/06/09)	ABT00602545-602578				X		06/12/09
PX 97	HUMIRA SALES ADVERTISEMENT. (LUBBERT, 02/06/09)	ABT00186245-186256				X		06/12/09
PX 105	SUMMARY FOR NORTH AMERICAN ADVISORY BOARD ON CROHN'S DISEASE DATED 05/11/07 AT WESTIN O'HARE, CHICAGO. (LUBBERT, 02/06/09)	ABT00600812-600820			H, A			
PX 106	PRESENTATION ENTITLED, "BE FIRST" BY CHERYL LUBBERT DATED 01/2008. (LUBBERT, 02/06/09)	ABT01068469-1068494				X		06/12/09
PX 107	PRESENTATION ENTITLED, "WORKING TOGETHER WE CAN MAKE A DIFFERENCE" BY CHERYL LUBBERT DATED 04/2008. (LUBBERT, 02/06/09)	ABT00822730-822758				X		06/12/09
PX 108	HUMIRA GASTRO TI MARKETING UPDATE. (LUBBERT, 02/06/09)	ABT00716799-716855				X		06/12/09
PX 109	CHARTS REFLECTING FINANCIALS/ACTUALS SPILT OUT BY DIFFERENT INDICATIONS. (LUBBERT, 02/06/09)	ABT01373203-1373208				X		06/12/09
PX 110	SERIES OF PROFIT AND LOSS STATEMENTS FOR PHARMACEUTICAL PRODUCTS DIVISION TOTAL IMMUNOLOGY DATED 2002-2008. (LUBBERT, 02/06/09)	ABT01374641-1374653				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 111	PHARMACEUTICAL PRODUCTS DIVISION TOTAL 2004 ACTUALS KEY PRODUCT P&L. (LUBBERT, 02/06/09)	ABT01373021-1373066				X		06/12/09
PX 112	PHARMACEUTICAL PRODUCTS DIVISION TOTAL 2005 ACTUALS AND UPDATE - KEY PRODUCT P&L. (LUBBERT, 02/06/09)	ABT01116117-1116151				X		06/12/09
PX 113	PHARMACEUTICAL PRODUCTS DIVISION TOTAL 2006 ACTUALS VS UPDATE - KEY PRODUCT P&L. (LUBBERT, 02/06/09)	ABT01116328-1116377				X		06/12/09
PX 114	PHARMACEUTICAL PRODUCTS DIVISION TOTAL 2007 ACTUALS VS UPDATE - KEY PRODUCT P&L. (LUBBERT, 02/06/09)	ABT01116152-1116327				X		06/12/09
PX 115	PHARMACEUTICAL PRODUCTS DIVISION TOTAL 2008 ACTUALS VS UPDATE - KEY PRODUCT P&L. (LUBBERT, 02/06/09)	ABT01116378-1116527				X		06/12/09
PX 116	CHART REFLECTING INTERNATIONAL SALES BY COUNTRY SALES. (LUBBERT, 02/06/09)	ABT01373067-1373202				X		06/12/09
PX 117	PHARMACEUTICAL PRODUCTS DIVISION IMMUNOLOGY FRANCHISE EPIDEMIOLOGY SUMMARY FOR YEARS 2006-2012. (LUBBERT, 02/06/09)	ABT00727698-727756				X		06/12/09
PX 118	10/26/05 EMAIL FROM LEBOLD TO LYKE AND ANDERSON REGARDING ARTICLE ENTITLED, "CAMBRIDGE ANTIBODY TECHNOLOGY AND ABBOTT AGREE REGARDING ROYALTIES." (LUBBERT, 02/06/09)	ABT01054737-1054738			R. P			
PX 119	DEVELOPMENT AND LICENSE AGREEMENT BETWEEN CAT AND KNOLL DATED 04/01/95. (LUBBERT, 02/06/09)	ABT01373761-1373822				X		06/12/09
PX 120	SETTLEMENT AND AMENDMENT AGREEMENT BETWEEN CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED, CAMBRIDGE ANTIBODY TECHNOLOGY GROUP, ABBOTT BIOTECHNOLOGY LTD., ABBOTT GMBH & CO. KG AND ABBOTT LABORATORIES DATED 10/25/05. (LUBBERT, 02/06/09)	ABT01160277-1160297				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 121	NON-EXCLUSIVE LICENSE AGREEMENT BETWEEN CENTOCOR, INC. AND ABBOTT LABORATORIES (BERMUDA) LIMITED AND ABBOTT BIOTECHNOLOGY LIMITED DATED 12/23/02. (LUBBERT, 02/06/09)					X		06/12/09
PX 122	LICENSE AGREEMENT BETWEEN THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK AND BASF BIORESEARCH CORPORATION DATED 06/01/95. (LUBBERT, 02/06/09)	ABT01373724-1373731				X		06/12/09
PX 123	PATENT LICENSE AGREEMENT BETWEEN THE WELLCOME FOUNDATION LIMITED, GLAXO GROUP LIMITED, SMITHKLINE BEECHAM CORPORATION AND ABBOTT LABORATORIES LIMITED DATED 12/12/02. (LUBBERT, 02/06/09)	ABT01373253-1373279				X		06/12/09
PX 124	PATENT LICENSE AGREEMENT BETWEEN THE WELLCOME FOUNDATION LIMITED, GLAXO GROUP LIMITED, SMITHKLINE BEECHAM CORPORATION AND ABBOTT LABORATORIES LIMITED DATED 12/12/02. (LUBBERT, 02/06/09)	ABT01373226-1373252				X		06/12/09
PX 125	AGREEMENT BETWEEN GRUNENTHAL GMBH, BASF AKTIENGESSELLSCHAFT AND KNOLL AG DATED 09/14/01. (LUBBERT, 02/06/09)	ABT00316961-316971				X		06/12/09
PX 126	LICENSE AGREEMENT BETWEEN INTERLAB LTD. AND KNOLL AG DATED 03/15/00. (LUBBERT, 02/06/09)	ABT01373398-1373413				X		06/12/09
PX 127	SUB-LICENSE BETWEEN MEDICAL RESEARCH COUNCIL AND KNOLL AG DATED 06/29/93. (LUBBERT, 02/06/09)	ABT01373524-1373544				X		06/12/09
PX 128	AGREEMENT BETWEEN THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY AND KNOLL DATED 05/17/95. (LUBBERT, 02/06/09)	ABT01373513-1373523				X		06/12/09
PX 129	11/16/05 EMAIL FROM LEBOLD TO WHITE, CONWAY AND JOHNSON REGARDING ATTACHED DRAFT LICENSE AGREEMENT BETWEEN KENNEDY AND ABBOTT. (LUBBERT, 02/06/09)	ABT00968590-968612			R, A, F			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 130	12/14/05 EMAIL FROM POULOS TO HEYMAN, SCODARI AND DEMPSEY REGARDING DECEMBER 13 MEETING AND NEXT STEPS. (LUBBERT, 02/06/09)	ABT00977731			R, FRE 408, P			
PX 131	07/05/06 EMAIL FROM DEMPSEY TO YASGER, POULOS, RIVERA AND HALE REGARDING CENTOCOR TNF-ALPHA. (LUBBERT, 02/06/09)	ABT01361501-1361502			R			
PX 132	I&J IL-12 ANALYSIS DATED 04/21/06. (LUBBERT, 02/06/09)	ABT00977845-977863			R, F, FRE 408, P			
PX 133	09/24/07 EMAIL FROM COOK TO POULOS REGARDING IL-12 IP SWAP AND NON-BINDING SUMMARY OF PROPOSED TERMS FOR AGREEMENT WITH I&J. (LUBBERT, 02/06/09)	ABT00977876-977885			R, FRE 408, P			
PX 134	PRESENTATION ENTITLED, "THE DISCOVERY AND THE DEVELOPMENT OF HUMIRA" BY KAYMAKALAN DATED 10/05/07. (KAYMAKALAN, 02/24/09)	ABT01089662-1089710				X		06/12/09
PX 135	DRAFT REPORT REGARDING CHARACTERIZATION OF A FULLY HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR HUMAN TNF-ALPHA. (KAYMAKALAN, 02/24/09)	ABT00400041-400057			O	X		06/12/09
PX 136	REPORT ENTITLED, "MOLECULAR CHARACTERIZATION OF MAK 195F ANTI-TNF ANTIBODY." (KAYMAKALAN, 02/24/09)	ABT00392514-392543			O	X		06/12/09
PX 137	PRESENTATION BY KAYMAKALAN ENTITLED, "HUMIRA MOA STUDIES" DATED UPDATE-07/01/05. (KAYMAKALAN, 02/24/09)	ABT01094444-1094453				X		06/12/09
PX 138	09/05/03 EMAIL FROM DIXON TO KAYMAKALAN REGARDING CONTACT LIST. (KAYMAKALAN, 02/24/09)	ABT00403501-403502			H			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 139	01/25/02 PRECLINICAL REPORT ENTITLED, "CHARACTERIZATION AND ASSESSMENT OF HABA SAMPLES FORM DE003, DE007, DE009, DE011 AND DE024C STUDIES IN ADALIMUMAB-F AND HU-IGG ELISAS AND L929 BIOASSAYS" AUTHORED BY KAYMAKALAN. (KAYMAKALAN, 02/24/09)	ABT00151969-152025				X		06/12/09
PX 140	07/16/96 REPORT FROM SAKORAFAS ENTITLED, "HUMAN MONOCLONAL ANTIBODIES (APRIL, MAY, JUNE 1996)." (SAKORAFAS, 03/06/09)	ABT00635592-635594				X		06/12/09
PX 141	SUMMARY OF ACTIVITIES IN SUPPORT OF D2E7 VERSUS MAK195 COMPARABILITY STUDIES USING CAPTURE METHOD WITH IODINATED TNF. (SAKORAFAS, 03/06/09)	ABT00248885				X		06/12/09
PX 142	U937 SCATCHARD PLOT ANALYSIS DATED 08/10/95. (SAKORAFAS, 03/09/09)	ABT00232235				X		06/12/09
PX 143	LAB NOTEBOOK NO. 25189-19 ASSIGNED TO PAUL SAKORAFAS. (SAKORAFAS, 03/09/09)	ABT00070013-70294				X		06/12/09
PX 144	CHART ENTITLED, "BINDING OF I-125 rhTNF TO IMMOBILIZED BIOTINYLATED ANTI-rhTNF ANTIBODY." (SAKORAFAS, 03/09/09)	ABT00248895-248897				X		06/12/09
PX 145	LAB NOTEBOOK NO. 25189-18 ASSIGNED TO PAUL SAKORAFAS. (SAKORAFAS, 03/09/09)	ABT00069736-70012				X		06/12/09
PX 146	07/08/98 FAX MESSAGE FROM THE JOURNAL OF IMMUNOLOGY TO KAYMAKALAN REGARDING ACKNOWLEDGMENT OF RECEIPT OF MANUSCRIPT. (SAKORAFAS, 03/09/09)	ABT00392549				X		06/12/09
PX 147	PRESENTATION REGARDING EXCITING RESEARCH APPLICATIONS USING BIOMOLECULAR INTERACTION ANALYSIS BY SAKORAFAS DATED 12/10/03. (SAKORAFAS, 03/09/09)	ABT00404142-404201				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 148	TECHNICAL REPORT ABC/R343 ENTITLED, "DETERMINATION OF ABT-325 BINDING PATTERNS (EPI TOPE MAPPING) AND TESTING CROSS REACTIVITY USING BIACORE." BY SAKORAFAS DATED 05/13/05. (SAKORAFAS, 03/09/09)	ABT00415992-416014			O, R			
PX 149	11/21/02 EMAIL FROM SAKORAFAS TO KAYMAKALAN REGARDING COMPLETE PAIR-WISE EPI TOPE MAPPING USING GOAT ANTI-MOUSE IgG. (SAKORAFAS, 03/09/09)	ABT00158610-158615			R, O, F, P			
PX 150	LAB NOTEBOOK ASSIGNED TO PAUL SAKORAFAS DATED 01/10/03. (SAKORAFAS, 03/09/09)	ABT01393787-1393990			R, O, F, P			
PX 151	11/29/02 EMAIL FROM SAKORAFAS TO KAYMAKALAN REGARDING COMPLETE EPI TOPE MAPPING USING CAPTURED REMICADE, D2E7 AND SEGARD. (SAKORAFAS, 03/09/09)	ABT00161646-161659			R, O, F, P			
PX 152	12/02/02 EMAIL STRING FROM SAKORAFAS TO KAYMAKALAN REGARDING COMPLETE EPI TOPE MAPPING USING CAPTURED REMICADE, D2E7 AND SEGARD. (SAKORAFAS, 03/09/09)	ABT00161660			R, O, F, P			
PX 153	12/30/02 MEMO FROM SAKORAFAS TO KAYMAKALAN REGARDING PEPTIDE EPI TOPE MAPPING. (SAKORAFAS, 03/09/09)	ABT00158637			R, O, F, P			
PX 154	07/24/03 EMAIL FROM KAYMAKALAN TO SAKORAFAS, SANTORA, XIONG AND KARAOGLU REGARDING PATENT RELATED ANTIBODIES. (SAKORAFAS, 03/09/09)	ABT01393994 ABT0158638-158648			R, F, P, O			
PX 155	12/13/05 EMAIL FROM HEYMAN TO DOW, SCODARI AND MCGINN REGARDING NOTICE OF ALLOWANCE. (DOW, 03/11/09)	CCOR01707885			H, P			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 156	12/13/05 EMAIL STRING FROM DOW TO JOHNSON, PLANTZ, HEYMAN, MCGINN, SCODARI AND TOWNSEND REGARDING ISSUE FEE PAID FOR US SERIAL NO. 10/198,845. (DOW, 03/11/09)	CCOR01791385-1791386			H, FRE 408, P	X		06/19/09 Non-highlighted Orange highlighted portions in
PX 157	12/21/05 EMAIL STRING FROM DOW TO SCODARI, HEYMAN AND JOHNSON REGARDING TNF PATENT. (DOW, 03/11/09)	CCOR01791387			H, FRE 408, P			
PX 158	01/06/06 EMAIL STRING FROM DOW TO PLANTZ AND JOHNSON REGARDING PROJECT AUGUST. (DOW, 03/11/09)	CCOR01791388			H, FRE 408, P, R	X		06/19/09 Non-highlighted Orange highlighted portions in
PX 159	02/06/06 EMAIL STRING FROM DOW TO MCGINN, HEYMAN AND ANDERSON REGARDING ABBOTT. (DOW, 03/11/09)	CCOR01707883-1707884			H, FRE 408, P, R			
PX 160	02/13/06 EMAIL STRING FROM DOW TO JOHNSON, SCODARI, HEYMAN, PLANTZ AND MCGINN REGARDING DEBERADINE CALL. (DOW, 03/11/09)	CCOR01707889			H, FRE 408, P, R	X		06/19/09 Non-highlighted Orange highlighted portions in
PX 161	03/12/06 EMAIL FROM SCODARI TO DOW, HEYMAN, JOHNSON, MCGINN, JOHNSON, MCHUGH, SIEGEL, ANDERSON, DICHTER, TOWNSEND, PLANTZ AND FISCHER REGARDING PROJECT AUGUST TERM SHEET. (DOW, 03/11/09)	CCOR01707886-1707887			H, FRE 408, P, R	X		06/19/09 Non-highlighted Orange highlighted portions in

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 162	04/09/92 MINUTES OF CAT MEETING WITH HANDWRITTEN NOTES. (MANKOVICH, 03/17/09)	ABT00173921-173922			R	X		06/19/09 Admissible to show what was discussed at meeting, but not truth of what was said at meeting
PX 163	09/29/92 HANDWRITTEN MEETING NOTES. (MANKOVICH, 03/17/09)	ABT00511054			R, A, F	X		06/19/09 Admissible to show what was discussed at meeting, but not truth of what was said at meeting
PX 164	09/02/92 HANDWRITTEN MEETING NOTES REGARDING CAT/GENPHARM DISCUSSIONS. (MANKOVICH, 03/17/09)	ABT00511033			R, A, F	X		06/19/09 Admissible to show what was discussed at meeting, but not truth of what was said at meeting
PX 165	06/02/92 MEMO FROM MOELLER AND TRACEY TO BERSTEIN, KAMEN, KEILHAUER, MANKOVICH, MCRAE, RATNOFSKY, SALFELD AND WONG REGARDING HUMAN MONOCLONAL ANTIBODIES MEETING. (MANKOVICH, 03/17/09)	ABT00176853-176854			R, A, F			
PX 166	06/16/92 MEMO FROM ZAGLAKAS TO KAMEN, MANKOVICH, MOELLER, SALFELD AND TRACEY REGARDING COPY OF CAT CONFIDENTIAL PREPRINT. (MANKOVICH, 03/17/09)	ABT00510973-510980				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 167	ARTICLE ENTITLED, "BY-PASSING IMMUNIZATION: BUILDING HIGH AFFINITY HUMAN ANTIBODIES BY CHAIN SHUFFLING," BY MARKS ET AL. ISSUED IN BIOTECHNOLOGY, VOL. 30, JULY 1992. (MANKOVICH, 03/17/09)	CCOR01725945-1725950				X		06/12/09
PX 168	08/11/92 MEMO FROM SALFELD TO KAMEN, TRACEY, SCHOLLMEIER, MOELLER, MANKOVICH AND RATNOFSKY REGARDING GENPHARM - CONVERSATION WITH NILS LONBERG. (MANKOVICH, 03/17/09)	ABT00362036-362075			R, A, F			
PX 169	10/01/92 MEMO FROM MANKOVICH, SALFELD AND TRACEY TO SCHOLLMEIER REGARDING CAT PROPOSAL. (MANKOVICH, 03/17/09)	ABT00173875-173877				X		06/12/09
PX 170	QUARTERLY REPORT DATED 1995 BY MANKOVICH - MOLECULAR BIOLOGY GROUP. (MANKOVICH, 03/17/09)	ABT00635598-635599				X		06/12/09
PX 171	QUARTERLY REPORT DATED 1996 BY MANKOVICH - MOLECULAR BIOLOGY GROUP. (MANKOVICH, 03/17/09)	ABT00187730-187731				X		06/12/09
PX 172	QUARTERLY REPORT DATED 1996 BY MANKOVICH - MOLECULAR BIOLOGY GROUP. REDACTED (MANKOVICH, 03/17/09)	ABT00199479-199481				X		06/12/09
PX 173	MATERIALS FROM 1991 SECOND ANNUAL IBC INTERNATIONAL CONFERENCE ON ANTIBODY ENGINEERING. (MANKOVICH, 03/17/09)	CCOR01792163-1792274				X		06/12/09
PX 174	MATERIALS FROM 1991 SECOND ANNUAL IBC INTERNATIONAL CONFERENCE ON ANTIBODY ENGINEERING - PRODUCTION OF A SINGLE-CHAIN BI-SPECIFIC ANTIBODY BY GEORGE. (MANKOVICH, 03/17/09)	CCOR01792277-1792461				X		06/12/09
PX 175	ARTICLE ENTITLED, "GENERATION OF A LARGE COMBINATORIAL LIBRARY OF THE IMMUNOGLOBULIN REPERTOIRE IN PHAGE LAMBDA." BY HUSE ET AL. AND ISSUED IN SCIENCE, 8 DECEMBER 1989, VOL. 246, PAGES 1213-1360 (MANKOVICH, 03/17/09)	CCOR00390650-390658				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 176	ARTICLE ENTITLED, "PHAGE ANTIBODIES: FILAMENTOUS PHAGE DISPLAYING ANTIBODY VARIABLE DOMAINS," AUTHORED BY MCCAFFERTY ET AL. AND PUBLISHED IN NATURE, VOL. 348, 6 DECEMBER 1990. (MANKOVICH, 03/17/09)	CCOR00390566-390570				X		06/12/09
PX 177	ARTICLE ENTITLED, "MAKING ANTIBODY FRAGMENTS USING PHAGE DISPLAY LIBRARIES," AUTHORED BY CLACKSON ET AL. AND PUBLISHED IN NATURE, VOL. 352, 15 AUGUST 1991. (MANKOVICH, 03/17/09)	CCOR00390643-390649				X		06/12/09
PX 178	ARTICLE ENTITLED, "LINKAGE OF RECOGNITION AND REPLICATION FUNCTIONS BY ASSEMBLING COMBINATORIAL ANTIBODY FAB LIBRARIES ALONG PHAGE SURFACES," AUTHORED BY KANG ET AL. AND PUBLISHED IN PROC. NATL. ACAD. SCI. USA VOL. 88, PP. 4363-4366, MAY 1991 BIOCHEMISTRY. (MANKOVICH, 03/17/09)	CCOR00390722-390725				X		06/12/09
PX 179	ARTICLE ENTITLED, "BY-PASSING IMMUNIZATION HUMAN ANTIBODIES FROM V-GENE LIBRARIES DISPLAYED PHAGE," AUTHORED BY MARKS ET AL. AND PUBLISHED IN J. MOL. BIOL. (1991) 222, 581-597. (MANKOVICH, 03/17/09)	ABT00262901-262918				X		06/12/09
PX 180	ARTICLE ENTITLED, "ANTIBODY REDESIGN BY CHAIN SHUFFLING FROM RANDOM COMBINATORIAL IMMUNOGLOBULIN LIBRARIES," AUTHORED BY KANG ET AL. AND PUBLISHED IN PROC. NATL. ACAD. SCI. USA VOL. 88, PP. 11120-11123, DECEMBER 1991 IMMUNOLOGY. (MANKOVICH, 03/17/09)	CCOR00390711-390714				X		06/12/09
PX 181	11/17/05 EXPERT REPORT OF ROBERT KAMEN, PH.D. (KAMEN, 03/25/09)	ABT01394252-1394297			H, R			
PX 182	02/15/06 DEPOSITION TRANSCRIPT OF ROBERT KAMEN, PH.D. (KAMEN, 03/25/09)	ABT01394169-1394251			R			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 183	04/07/93 MINUTES FROM HUMAB PROJECT TEAM MEETING ON 03/24/93. (KAMEN, 03/25/09)	ABT00176915-176918				X		06/12/09
PX 184	01/19/95 MEMO FROM TRACEY TO CORWIN, SPIGELMAN, FISCHKOFF, DAUM, KEMPENI, SCHLICK, KAMEN, Salfeld, KAYMAKALAN, BANERJEE, MOESTA AND AVGERINOS REGARDING SUMMARY OF MEETING HELD AT BBC WITH RHEUMATOLOGY CONSULTANT DISCUSSING USE OF HUMAN ANTI-TNF ANTIBODY IN RHEUMATOID ARTHRITIS. (KAMEN, 03/25/09)	ABT00195829-195839			A, F, H			
PX 185	03/12/93 MEMO FROM TRACEY TO DAUM, KAUL, KEMPENI, SPIGELMAN, KAMEN, MCRAE, MOELLER AND Salfeld REGARDING ANTI-TNF EFFECTS IN RHEUMATOID ARTHRITIS. (KAMEN, 03/25/09)	ABT00194924-194926			H			
PX 186	WO 90/05144 ISSUED TO WINTER ET AL. FOR "SINGLE DOMAIN LIGANDS, RECEPTORS COMPRISING SAID LIGANDS, METHODS FOR THEIR PRODUCTION AND USE OF SAID LIGANDS AND RECEPTORS." (KAMEN, 03/25/09)	ABT00260441-260537				X		06/12/09
PX 187	WO 92/01047 ISSUED TO MCCAFFERTY ET AL. FOR "METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS." (KAMEN, 03/25/09)	ABT00260538-260749				X		06/12/09
PX 188	WO 93/06213 ISSUED TO HOOGENBOOM ET AL. FOR "PRODUCTION OF CHIMERIC ANTIBODIES - A COMBINATORIAL APPROACH." (KAMEN, 03/25/09)	ABT00260301-260409				X		06/12/09
PX 189	01/31/00 FAX FROM SCHLICK TO GRAU, ECKERT, SPIGELMAN, SPIGLER, MUNSCHAUER, MARTIN AND KAMEN REGARDING REVIEW OF D2E7 VALUE PROPOSITION. (KAMEN, 03/25/09)	ABT00200181-200184			F, A, H, O, R, P			
PX 190	03/20/09 EXPERT REPORT OF RANDALL LAWRENCE KINCAID. (KINCAID, 04/02/09)							
PX 191	ARTICLE ENTITLED, "CONSTRUCTION AND INITIAL CHARACTERIZATION OF A MOUSE-HUMAN CHIMERIC ANTI-TNF ANTIBODY,"	CCOR00028558-28568				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
	AUTHORED BY KNIGHT ET AL., PUBLISHED IN MOLECULAR IMMUNOLOGY, VOL. 30, NO. 16, PP. 1443-1453, 1993. (KINCAID, 04/02/09)							
PX 192	ARTICLE, "MONOCLONAL ANTIBODIES TO HUMAN TUMOR NECROSIS FACTOR α : IN VITRO AND IN VIVO APPLICATION," AUTHORED BY MOELLER ET AL. AND PUBLISHED IN CYTOKINE, VOL. 2, NO.3 (MAY), 1990: PP. 162-169. (KINCAID, 04/02/09)	CCOR00011485-11492				X		06/12/09
PX 193	US PATENT 5,231,024 ISSUED TO MOELLER ET AL. ENTITLED, "MONOCLONAL ANTIBODIES AGAINST HUMAN TUMOR NECROSIS FACTOR (TNF) AND USE THEREOF." (KINCAID, 04/02/09)					X		06/12/09
PX 194	UK PATENT APPLICATION GB 2279077 ISSUED TO BODMER ET AL. ENTITLED, "RECOMBINANT ANTIBODIES SPECIFIC FOR TNF-ALPHA." (KINCAID, 04/02/09)					X		06/12/09
PX 195	WO 91/02078 ISSUED TO RATHJEN ET AL. ENTITLED, "TUMOUR NECROSIS FACTOR BINDING LIGANDS." (KINCAID, 04/02/09)					X		06/12/09
PX 196	FIGURE 4 - COMPETITIVE ELISA WITH A2 AND MAK-195 WITH ANNOTATIONS. (KINCAID, 04/02/09)				R			
PX 197	ARTICLE ENTITLED, "A RAPID AND SENSITIVE METHOD FOR DETECTION AND QUANTIFICATION OF CALCINEURIN AND CALMODULIN-BINDING PROTEINS USING BIOTINYLATED CALMODULIN," AUTHORED BY BILLINGSLEY ET AL. AND PUBLISHED IN PROC. NATL. ACAD. SCI. USA, VOL. 82, PP. 7585-7589, NOVEMBER 1985 BIOCHEMISTRY. (KINCAID, 04/02/09)				R			
PX 198	ARTICLE ENTITLED, "PREPARATION OF FLUORESCENT, CROSS-LINKING, AND BIOTINYLATED CALMODULIN DERIVATIVES AND THEIR USE IN STUDIES OF CALMODULIN-ACTIVATED PHOSPHODIESTERASE AND PROTEIN PHOSPHATASE," AUTHORED BY				R			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
	KINCAID ET AL. AND PUBLISHED IN METHODS IN ENZYMOLOGY, VOL. 159. (KINCAID, 04/02/09)							
PX 199	03/20/09 DEFENDANT ABBOTT LABORATORIES' EXPERT REPORT OF DR. JAMES D. MARKS, M.D., PH.D. (MARKS, 04/09/09)							
PX 200	04/06/09 DEFENDANT ABBOTT LABORATORIES' REBUTTAL EXPERT REPORT OF DR. JAMES D. MARKS, M.D., PH.D. (MARKS, 04/09/09)							
PX 201	EXHIBIT 155 - ANTICIPATION AND OBVIOUSNESS CHART FROM MARKS' INVALIDITY REPORT. (MARKS, 04/09/09)	ABT-JM 000886-926			I, C			
PX 202	04/06/09 MEMORANDUM OPINION AND ORDER RELATED TO CLAIM CONSTRUCTION. (MARKS, 04/09/09)				F, P			
PX 203	PAGE 3 FROM EXPERT KINCAID'S REPORT. (MARKS, 04/09/09)				I, FRE 1002			
PX 204	WO 91/02078 ISSUED TO RATHJEN ENTITLED, "TUMOUR NECROSIS FACTOR BINDING LIGANDS." (MARKS, 04/09/09)	ABT00086869-86952				X		06/12/09
PX 205	03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT. (MARKS, 04/09/09)				H			
PX 206	03/18/09 DECLARATION OF SUSAN TAM. (MARKS, 04/09/09)				H			
PX 207	ARTICLE ENTITLED, "A COMPLEMENTARITY- DETERMINING REGION SYNTHETIC PEPTIDE ACTS AS A MINIANIBODY AND NEUTRALIZES HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO," AUTHORED BY LEVI ET AL. AND PUBLISHED IN PROC. NATL. ACAD. SCI. USA VOL. 90, PP. 4374-4378, MAY 1993 IMMUNOLOGY. (MARKS, 04/09/09)					X		06/12/09
PX 208	MARKS' NOTES RELATED TO PX-207. (MARKS, 04/09/09)				R			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 209	ARTICLE ENTITLED, "HUMAN-HUMAN HYBRIDOMA AUTOANTIBODIES WITH BOTH ANTI-DNA AND RHEUMATOID FACTOR ACTIVITIES," AUTHORED BY RAUSCH ET AL. AND PUBLISHED IN THE JOURNAL OF CLINICAL INVESTIGATION, JANUARY 1986, VOL. 77, NUMBER 1, PP. 106-112. (MARKS, 04/09/09)	CCOR01792568-1792576				X		06/12/09
PX 210	ARTICLE ENTITLED, "RAPID CLONING OF REARRANGED IMMUNOGLOBULIN GENES FROM HUMAN HYBRIDOMA CELLS USING MIXED PRIMERS AND THE POLYMERASE CHAIN REACTION," AUTHORED BY LARRICK ET AL. AND PUBLISHED IN BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, VOL. 160, NO. 3, 1989, MAY 15, 1989. (MARKS, 04/09/09)	CCOR01792659-1792665				X		06/12/09
PX 211	02/18/06 MEMO FROM YAN TO VON BORCKE, TAYLOR, SCHEIDLER AND FILAR REGARDING HUMIRA COMPETITOR SLIDE PRESENTATION. (SCHEIDLER, 02/20/09)	ABT00463555-463589			F	X		06/12/09
PX 212	03/16/06 EMAIL STRING WITH ATTACHMENT FROM SHAHDA TO SCHEIDLER, CARSON AND MILLER REGARDING 2006 BUDGET AND 2005 SPENDING. (SCHEIDLER, 02/20/09)	ABT00464157-464220			R			
PX 213	06/30/06 EMAIL FROM SCHEIDLER TO THOMPSON REGARDING 2007 RHEUM PLAN COMMENTS. (SCHEIDLER, 02/20/09)	ABT00471623-471768				X		06/12/09
PX 214	12/21/06 EMAIL STRING FROM SCHEIDLER TO EL-RASHIDY, LUBBERT, WRIGHT, YAN, WALESKA, FILAR AND TATSUKAWA REGARDING RA SHARE OF NEW PATIENT STARTS - 2007 LRP. (SCHEIDLER, 02/20/09)	ABT00470989-471019			P, O			
PX 215	03/26/07 EMAIL WITH ATTACHMENT FROM SCHEIDLER TO OLSON, VAUGHN, ZUCHNIK, WRIGHT, LUBBERT, TATSUKAWA, STEGMAN AND WEILER REGARDING RM DM RHEUM MARKETING OVERVIEW EAS V3. (SCHEIDLER, 02/20/09)	ABT00796773-796806			H			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 216	05/07/07 EMAIL STRING WITH ATTACHMENT FROM SCHEIDLER TO JONES REGARDING REQUESTS – 2007 PLAN. (SCHEIDLER, 02/20/09)	ABT01305879-1305986			H	X		06/12/09
PX 217	05/17/07 EMAIL STRING WITH ATTACHMENT FROM SCHEIDLER TO JONES REGARDING SLIDES TO DISCUSS WHITE KNIGHT STRATEGY VS INFUSED AGENTS. (SCHEIDLER, 02/20/09)	ABT01313268-1313288			H			
PX 218	07/13/07 EMAIL WITH ATTACHMENT FROM SCHEIDLER TO JONES, TATSUKAWA, GRAFF, SINGH, REDIG, NELLES, STEGMAN AND CIFALDI REGARDING RHEUM PLAN SLIDES FOR TYREE MEETING. (SCHEIDLER, 02/20/09)	ABT01323252-1323307			H	X		06/12/09
PX 219	08/15/07 EMAIL STRING FROM SCHEIDLER TO ABBOTT, CONNELL, JAMES, JONES AND WALESKA REGARDING UPDATE RE: HUMIRA BURNING AND STINGING. (SCHEIDLER, 02/20/09)	ABT00468665-468667			H			
PX 220	PRESENTATION BY SCHEIDLER ENTITLED, “SEPTEMBER ’07 RM/DM – RHEUMATOLOGY REVIEW.” (SCHEIDLER, 02/20/09)	ABT01331538-1331574				X		06/12/09
PX 221	01/09/08 EMAIL STRING FROM LICKTEIG TO DISTRIBUTION REGARDING DECEMBER 2007 MONTHLY IMMUNOLOGY CI SUMMARY. (SCHEIDLER, 02/20/09)	ABT01066977-1066982			H			
PX 222	01/10/08 EMAIL WITH AN ATTACHMENT FROM HEBBELN TO SCHEIDLER, JOHNSON AND JONES REGARDING COMPETITIVE SIMULATION MATERIALS. (SCHEIDLER, 02/20/09)	ABT01343400-1343456			P, R			
PX 223	06/25/08 EMAIL STRING WITH ATTACHMENT FROM SCHEIDLER TO LUBBERT, HEBBELN, SINGH, TATSUKAWA, GRAFF AND JONES REGARDING PHEUM COMPETITOR RESPONSE PLAN UPDATE. (SCHEIDLER, 02/20/09)	ABT01276629-1276721				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 224	04/11/07 EMAIL STRING WITH ATTACHMENT FROM SCHEIDLER TO JONES REGARDING MONITOR HUMIRA GROWTH PATH RA KICK-OFF DECK FOR TOMORROW. (SCHEIDLER, 02/20/09)	ABT01303071-1303105				X		06/12/09
PX 225	05/16/07 EMAIL WITH ATTACHMENT FROM LUBBERT TO LUCE AND JONES REGARDING MONITOR PROJECT. (SCHEIDLER, 02/20/09)	ABT00600368-600417				X		06/12/09
PX 226	07/17/07 EMAIL STRING WITH ATTACHMENT FROM JONES TO SCHEIDLER REGARDING MONITOR/DOBLIN APPROACH FOR HUMIRA AFFINITY PROJECT. (SCHEIDLER, 02/20/09)	ABT01323398-1323465				X		06/12/09
PX 227	01/06/09 DEFENDANTS' OBJECTIONS TO NOTICE OF DEPOSITION PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 30(B)(6). (HOFFMAN, 02/26/09)					X		06/12/09
PX 228	01/30/09 LETTER FROM MAJOR TO MASLOWSKI REGARDING DEPOSITION SCHEDULING AND HOFFMAN SERVING AS ABBOTT'S REPRESENTATIVE IN RESPONDING TO TOPICS 3 AND 7VI. (HOFFMAN, 02/26/09)					X		06/12/09
PX 229	02/25/09 EMAIL STRING FROM MAJOR TO VERRECCHIO REGARDING HOFFMAN SERVING AS ABBOTT'S REPRESENTATIVE ON TOPIC 14. (HOFFMAN, 02/26/09)					X		06/12/09
PX 230	PRESS RELEASE - ABBOTT'S HUMIRA (ADALIMUMAB) HONORED WITH PRESTIGIOUS GALEN PRIZE FOR INNOVATION IN PATIENT CARE. (HOFFMAN, 02/26/09)	ABT00341208-341211				X		06/12/09
PX 231	10/06/00 ARTICLE FROM INTERNET SOURCE ENTITLED, "SCHERING PLOUGH WINS PRESTIGIOUS PHARMACEUTICAL AWARD FOR REMICADE." (HOFFMAN, 02/26/09)				F, A			
PX 232	CHART REFLECTING HUMIRA R&D EXPENSES FOR 2001-2008. (HOFFMAN, 02/26/09)					X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 233	ARTICLE ENTITLED, "REVOLUTION AND EVOLUTION: FROM D2E7 TO HUMIRA," AUTHORED BY HOFFMAN AND SALFELD. (HOFFMAN, 02/26/09)	ABT00356805-356806				X		06/12/09
PX 234	US PRODUCT LABEL FOR HUMIRA DATED DECEMBER 2008. (HOFFMAN, 02/26/09)					X		06/12/09
PX 235	PRESENTATION ENTITLED, "THE STAR TRIAL - SAFETY-TRIAL ADALIMUMAB IN RHEUMATOID ARTHRITIS," BY HOFFMAN. (HOFFMAN, 02/26/09)	ABT00217880-217906				X		06/12/09
PX 236	US PATENT 6,270,766 ISSUED TO FELDMAN ENTITLED, "ANTI-TNF ANTIBODIES AND METHOTREXATE IN THE TREATMENT OF ARTHRITIS AND CROHN'S DISEASE." (HOFFMAN, 02/26/09)	ABT00125103-125132			R			
PX 237	EUROPEAN PATENT SPECIFICATION EP 0914157 ISSUED TO FELDMAN ENTITLED, "ANTI-TNF ANTIBODIES/TNF RECEPTOR AND METHOTREXATE IN THE TREATMENT OF AUTOIMMUNE DISEASE." (HOFFMAN, 02/26/09)				R			
PX 238	02/01/06 LETTER FROM CONWAY TO WHITE REGARDING KENNEDY INSTITUTE OF PNEUMATOLOGY'S EUROPEAN PATENT 0914157 B1. (HOFFMAN, 02/26/09)	ABT00968552-968553			R, P, F			
PX 239	09/25/93 PUBLICATION ENTITLED, "THE ISOLATION OF HUMAN ANTIBODIES WITH HIGH AFFINITY FOR AND NEUTRALIZING ACTIVITY AGAINST HUMAN TNF α " BY HOOGENBOOM, ROBERTS AND ALLEN. (HOFFMAN, 02/26/09)	ABT00086577-86612				X		06/12/09
PX 240	MARCH 2002 - INTEGRATED SUMMARY OF EFFECTIVENESS DATA - ADALIMUMAB D2E7. (HOFFMAN, 02/26/09)	ABT00130161-130455				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 241	01/25/02 PRECLINICAL REPORT ENTITLED, "CHARACTERIZATION AND ASSESSMENT OF HABA SAMPLES FORM DE003, DE007, DE009, DE011 AND DE024C STUDIES IN ADALIMUMAB-F AND HU-IGG ELISAS AND L929 BIOASSAYS" AUTHORED BY KAYMAKALAN. (HOFFMAN, 02/26/09)	ABT00151969-152025				X		06/12/09
PX 242	03/05/08 EMAIL STRING FROM POLLACK TO MCILRAITH, SALFELD, JACQUES, KENT. HOFFMAN AND PAULSON REGARDING DISCUSS GI SLIDES. (HOFFMAN, 02/26/09)	ABT00964216-964222				X		06/12/09
PX 243	11/13/02 SUMMARY OF LABELLING DISCUSSION. (HOFFMAN, 02/26/09)	ABT00229098-229100			R, F			
PX 244	ARTICLE ENTITLED, "IMMUNOGENICITY, EFFICACY AND ADVERSE EVENTS OF ADALIMUMAB IN RA PATIENTS," AUTHORED BY BENDER ET AL. AND PUBLISHED IN RHEUMATOL INT. (HOFFMAN, 02/26/09)	ABT00755954-755959				X		06/12/09
PX 245	PRESENTATION ENTITLED, "OVERALL D2E7 STORY." (HOFFMAN, 02/26/09)	ABT00240099-240244			F			
PX 246	06/13/08 PRESENTATION ENTITLED, "HUMIRA/IMMUNOLOGY FRANCHISE 2009 PORTFOLIO STRATEGY." (HOFFMAN, 02/26/09)	ABT01273446-1273475				X		06/12/09
PX 247	04/06 CENTOCOR PRESENTATION - FINAL: PART 1 - REMICADE FOR ANKYLOSING SPONDYLITIS PATIENT RECORD STUDY.	CCOR01780099-1780160			H			
PX 248	04/06 CENTOCOR PRESENTATION - FINAL: PART 1 - REMICADE FOR PSORIATIC ARTHRITIS PATIENT RECORD STUDY.	CCOR01782339-1782411			H			
PX 249	05/31/07 CENTOCOR WAVE 26 DRAFT REPORT - REMICADE RHEUMATOID ARTHRITIS PERFORMANCE TRACKING WITH PHYS/PULSE.	CCOR01789496-1789570			H			
PX 250	11/16/07 CENTOCOR WAVE 27 DRAFT REPORT - REMICADE RHEUMATOID ARTHRITIS PERFORMANCE TRACKING WITH PHYS/PULSE.	CCOR01789571-1789626			H			
PX 251	06/10/08 CENTOCOR WAVE 28 FINAL REPORT - REMICADE RHEUMATOID ARTHRITIS PERFORMANCE TRACKING WITH PHYS/PULSE.	CCOR01789627-1789692			H		X	6/23/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 252	04/11/07 CENTOCOR FINAL REPORT - REMICADE RHEUMATOID ARTHRITIS RE-CONTACT STUDY.	CCOR01789693-1789780			H			
PX 253	03/22/06 CENTOCOR WAVE 24 FINAL REPORT - REMICADE RHEUMATOID ARTHRITIS PERFORMANCE TRACKING WITH PHYSPULSE.	CCOR01789781-1789852			H			
PX 254	07/20/06 CENTOCOR QUICKPULSE WAVE 1 FINAL REPORT - REMICADE RHEUMATOID ARTHRITIS QUICKPULSE.	CCOR01789833-1789920				X		06/12/09
PX 255	01/23/07 CENTOCOR QUICK PULSE 3 DRAFT - REMICADE PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS PERFORMANCE TRACKING WITH PHYSPULSE; RHEUMATOLOGISTS.	CCOR01790112-1790200			H			
PX 256	07/31/06 CENTOCOR WAVE 4 DRAFT REPORT - REMICADE PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS PERFORMANCE TRACKING WITH PHYSPULSE; RHEUMS.	CCOR01790201-1790255			H			
PX 257	01/30/08 CENTOCOR PHYSPULSE WAVE 6 DRAFT - REMICADE PSORIATIC ARTHRITIS PERFORMANCE TRACKING WITH PHYSPULSE; RHEUMATOLOGISTS.	CCOR01790333-1790382				X		06/12/09
PX 258	05/16/08 CENTOCOR WAVE 7 DRAFT REPORT PART 1: PSORIATIC ARTHRITIS - REMICADE PSORIATIC ARTHRITIS-ANKYLOSING SPONDYLITIS PERFORMANCE TRACKING WITH PHYSPULSE; RHEUMATOLOGISTS.	CCOR01790383-1790433			H			
PX 259	01/08/07 CENTOCOR WAVE 25 FINAL REPORT - REMICADE PSORIATIC ARTHRITIS PERFORMANCE TRACKING WITH PHYSPULSE.	CCOR01790629-1790705			H			
PX 260	09/22/08 CENTOCOR QP3 FINAL REPORT CROHN'S DISEASE - REMICADE CROHN'S DISEASE PERFORMANCE TRACKING WITH PHYSPULSE.	CCOR01790434-1790513			H			
PX 261	02/03/09 CENTOCOR W32 DRAFT REPORT PART I -- CROHN'S DISEASE - REMICADE INFLAMMATORY BOWEL DISEASE PERFORMANCE TRACKING WITH PHYSPULSE.	CCOR01790514-1790628			H		X	6/23/09
PX 262	01/08/07 CENTOCOR WAVE 25 FINAL REPORT - REMICADE RHEUMATOID ARTHRITIS PERFORMANCE TRACKING WITH PHYSPULSE.	CCOR01790629-1790705			H			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 263	05/23/07 CENTOCOR CROHN'S DISEASE QUICKPULSE DRAFT REPORT - REMICADE CROHN'S DISEASE PERFORMANCE TRACKING WITH QUICKPULSE.	CCOR01790706-1790755			H			
PX 264	05/04/07 CENTOCOR W28 DRAFT REPORT - REMICADE INFLAMMATORY BOWEL DISEASE PERFORMANCE TRACKING WITH PHYSYPULSE.	CCOR01790756-1790829			H			
PX 265	10/04/07 CENTOCOR W29 DRAFT REPORT PART 1 - CROHN'S DISEASE - REMICADE INFLAMMATORY BOWEL DISEASE PERFORMANCE TRACKING WITH PHYSYPULSE.	CCOR01790830-1790878			H			
PX 266	01/30/08 CENTOCOR PHYSYPULSE WAVE 6 DRAFT - REMICADE ANKYLOSING SPONDYLITIS PERFORMANCE TRACKING WITH PHYSYPULSE: RHEUMATOLOGISTS.	CCOR01791030-1791058			H			
PX 267	PRESENTATION ENTITLED, "DISCOVERY AND EARLY DEVELOPMENT OF INFLIXIMAB," BY KNIGHT.	CCOR00170761-170800			H, P			
PX 268	1988 LAB NOTEBOOK OF JUNMING LE -- PREPARATION AND CHARACTERIZATION OF MAB A2 (244) NEUTRALIZING HUMAN TNF.	LE00001-109				X		06/12/09
PX 269	04/18/06 EMAIL STRING FROM HEYMAN TO MCGINN REGARDING AUGUST.	CCOR01707890			H, P, R, FRE 408			
PX 270	11/07/03 EMAIL STRING FROM LEBOLD TO WHITE, MCGINN, DOW AND POPE REGARDING FOLLOW UP TO 11/6 MEETING.	CCOR01776966-1776976			H, P, R, FRE 408			
PX 271	01/09 CHART REFLECTING ESTIMATION OF THE PERCENT OF HUMIRA SYRINGES CO-ADMINISTERED WITH METHOTREXATE IN THE U.S. (HOLLINGER, 03/04/09)	ABT01389120			R			
PX 272	01/09 CHART REFLECTING ROYALTY CALCULATION OF THE HUMIRA SALES THAT ARE CO-ADMINISTERED WITH METHOTREXATE. (HOLLINGER, 03/04/09)	ABT01389121			R			
PX 273	SUMMARY OF THE METHOD USED TO ESTIMATE THE AMOUNT OF HUMIRA SYRINGES CO-ADMINISTERED WITH METHOTREXATE. (HOLLINGER, 03/04/09)	ABT01389187			R			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 274	01/09 CHART REFLECTING ESTIMATION OF THE HUMIRA SYRINGES CO-ADMINISTERED WITH METHOTREXATE WHERE CO-ADMINISTRATION IS DEFINED AS A METHOTREXATE CLAIM WITHIN SIX MONTHS BEFORE OR AFTER A HUMIRA CLAIM. (HOLLINGER, 03/04/09)	ABT01389626				X		06/12/09
PX 275	01/09 CHART REFLECTING ESTIMATED PERCENT OF HUMIRA'S SYRINGES CO-ADMINISTERED WITH METHOTREXATE WHERE ABBOTT'S DEFINES CO-ADMINISTRATION AS A HUMIRA CLAIM HAVING A METHOTREXATE CLAIM WITHIN ONE MONTH BEFORE OR AFTER THE HUMIRA CLAIM. (HOLLINGER, 03/04/09)	ABT01389627			R			
PX 276	01/09 CHART REFLECTING HUMIRA CLAIMS CO-ADMINISTERED WITH METHOTREXATE - BY DIAGNOSIS. (HOLLINGER, 03/04/09)				R			
PX 277	01/09 CHART REFLECTING HUMIRA CLAIMS CO-ADMINISTERED WITH METHOTREXATE - BY DIAGNOSIS (HOLLINGER, 03/04/09)				R			
PX 278	01/07/09 ABBOTT HUMIRA EXTRACT SPECIFICATION DOCUMENT PREPARED BY WOLTERS KLUWER HEALTH. (HOLLINGER, 03/04/09)				R			
PX 279	SCREEN SHOT OF FOLDER - OUTPUT RESULTS. (HOLLINGER, 03/04/09)				R			
PX 280	SCREEN SHOT OF FOLDER - RAW DATA. (HOLLINGER, 03/04/09)				R			
PX 281	EXCERPT FROM FILE RAW_HUMIRA_MTX_6.CSV. (HOLLINGER, 03/04/09)				R, I			
PX 282	EXCERPT FROM FILE RAW_HUMIRA_MTX_30. (HOLLINGER, 03/04/09)				R, I			
PX 283	EXCERPT FROM FILE RAW_HUMIRA_MTX_90. (HOLLINGER, 03/04/09)				R, I			
PX 284	EXCERPT FROM FILE ABT_106291_UB92_ICD9P_200707. (HOLLINGER, 03/04/09)				R, I			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 285	CHART REFLECTING ABBOTT INTERNATIONAL TOTAL HUMIRA SALES FOR SELECT COUNTRIES 2003-2008. (HOLLINGER, 03/04/09)	ABT1393736-1393737				X		06/12/09
PX 286	11/16/05 EMAIL WITH ATTACHMENT FROM LEBOLD TO WHITE, CONWAY AND JOHNSON REGARDING PROPOSED DIRECT LICENSE FOR REVIEW. (HOLLINGER, 03/04/09)	ABT01389126-1389151			R			
PX 287	CHART REFLECTING ESTIMATION OF THE PERCENT OF HUMIRA SYRINGES CO-ADMINISTERED WITH METHOTREXATE IN THE US. (HOLLINGER, 03/04/09)	ABT01389181-1389183			R			
PX 288	11/07/03 EMAIL WITH ATTACHMENT FROM LEBOLD TO WHITE REGARDING FOLLOW UP TO 11/6 MEETING. (HOLLINGER, 03/04/09)	ABT01389097-1389107			R			
PX 289	03/23/03 EMAIL WITH ATTACHMENT FROM LUCE TO HAMPTON, MCGUIRE AND SMITH REGARDING MESSAGE RECALL REPORT. (LUCE, 03/05/09)	ABT00608946-608987			H, F			
PX 290	09/03/03 EMAIL STRING FROM PHELPS TO DISTRIBUTION REGARDING TARGETRX 2Q '03 LAUNCH ASSESSMENT - HUMIRA. (LUCE, 03/05/09)	ABT00619887-619951			H, F			
PX 291	08/10/07 EMAIL STRING FROM LUCE TO TATSUKAWA AND PAUL REGARDING ENBREL PROGRAM UPDATE/HUMIRA NOW PROPOSAL. (LUCE, 03/05/09)	ABT00601881-601892				X		06/12/09
PX 292	08/31/07 PRESENTATION ENTITLED, "HUMIRA/RHEUMATOLOGY 2008 TACTICAL PLAN." (LUCE, 03/05/09)	ABT00435778-435814				X		06/12/09
PX 293	06/06/07 EMAIL WITH ATTACHMENT FROM LUCE TO KENNEY, LUBBERT, JONES, WRIGHT, KISELEV, RUSSO, SMITH AND KIRBY REGARDING EXPANSION WORKING DECK. (LUCE, 03/05/09)	ABT00593506-593533			F			
PX 294	10/07 PRESENTATION BY LUCE REGARDING IMMUNOLOGY. (LUCE, 03/05/09)	ABT01045788-1045810			F	X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 295	02/22/03 EMAIL STRING WITH ATTACHMENT FROM WALESKA TO DISTRIBUTION REGARDING FINAL DOCUMENT SUBMITTED TO DSG. (LUCE, 03/05/09)	ABT00615540-615576			L, F, O, P			
PX 296	04/02/08 PRESENTATION GIVEN BY LUCE AT THE REGIONAL MANAGER/DISTRICT MANAGER MEETING. (LUCE, 03/05/09)	ABT00605088-605124			F, H	X		06/12/09
PX 297	05/18/07 EMAIL STRING WITH ATTACHMENT FROM HAAS TO DUPREY REGARDING GASTRO MARKET RESEARCH STUDIES. (HAAS, 03/06/09)	ABT01074976-1075113			F, H	X		06/12/09
PX 298	04/17/08 EMAIL WITH ATTACHMENT FROM HAAS TO VAUGHAN, FILAR, PFAU, MUNRO AND KAHN REGARDING FINAL SIT ANALYSIS. (HAAS, 03/06/09)	ABT01064506-1064383			F	X		06/12/09
PX 299	07/16/07 EMAIL WITH ATTACHMENT FROM HAAS TO MAZZACCO REGARDING LAST SLIDE SET. (HAAS, 03/06/09)	ABT01069840-1069882			F, H	X		06/12/09
PX 300	06/22/07 EMAIL STRING WITH ATTACHMENT REGARDING LATEST GI PLAN. (HAAS, 03/06/09)	ABT01080322-1080369			F	X		06/12/09
PX 301	06/27/07 EMAIL STRING WITH ATTACHMENT FROM HAAS TO LICKTEIG AND VAUGHAN REGARDING COMPETITIVE DECK. (HAAS, 03/06/09)	ABT01064654-1064815				X		06/12/09
PX 302	04/22/08 EMAIL STRING FROM WANG TO DUPREY REGARDING PROPOSE GI STUDIES FOR TEC PRESENTATION. (HAAS, 03/06/09)	ABT01075377-1075380				X		06/12/09
PX 303	2D PICTURE GENERATED BY ARGIRIADI RELATED TO THE D2E7 COMPLEX TO TNF. (ARGIRIADI, 03/10/09)							
PX 304	2D PICTURE GENERATED BY ARGIRIADI RELATED TO TNF TIMER. (ARGIRIADI, 03/10/09)							
PX 305	05/02/07 EMAIL FROM ARGIRIADI TO SALFELD, TALANIAN AND BANACH REGARDING INTERFACE RESIDUES ON TNF. (ARGIRIADI, 03/10/09)	ABT00049125-49128				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 306	03/05 ABBOTT ORGANIZATIONAL CHART. (ARGIRIADI, 03/10/09)	ABT00104281-104312						
PX 307	05/03/07 EMAIL STRING WITH ATTACHMENT FROM ARGIRIADI TO SALFELD, TALANIAN, BANACH AND MANKOVICH REGARDING CONTACTS BETWEEN TNF AND HUMIRA OR TNFR. (ARGIRIADI, 03/10/09)	ABT00048589-49124						
PX 308	RAW DATA FILE. (ARGIRIADI, 03/10/09)	ABT00047160-47488			R			
PX 309	RAW DATA FILE. (ARGIRIADI, 03/10/09)	ABT00047875-48553			R			
PX 310	DENZO LOG. (ARGIRIADI, 03/10/09)	ABT00535891-535895			R			
PX 311	RAW DATA FILE. (ARGIRIADI, 03/10/09)	ABT00047520-47873			R			
PX 312	DIAGRAM CREATED BY ARGIRIADI ILLUSTRATING TWO FAB MOLECULES OF MAK195 COMPLEX TO TNF. (ARGIRIADI, 03/10/09)	ABT01374918						
PX 313	DIAGRAM CREATED BY ARGIRIADI ILLUSTRATING D2E7 COMPLEX TO TNF. (ARGIRIADI, 03/10/09)	ABT01393769						
PX 314	DIAGRAM CREATED BY ARGIRIADI ILLUSTRATING MAK195 BOUND TO TNF. (ARGIRIADI, 03/10/09)	ABT01393771						
PX 315	DIAGRAM CREATED BY ARGIRIADI ILLUSTRATING A SUPER POSITION OF TNF COMPLEX TO D2E7. (ARGIRIADI, 03/10/09)	ABT01393770						
PX 316	DIAGRAM CREATED BY ARGIRIADI ILLUSTRATING MAK195 COMPLEX TO TNF. (ARGIRIADI, 03/10/09)	ABT01393772						
PX 317	DOCUMENT GENERATED BY ARGIRIADI FOR CONTACT POINTS IN THE MAK STRUCTURE. (ARGIRIADI, 03/10/09)	ABT01393746-1393768						

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 318	02/15/06 EMAIL FROM BORHANI TO MANKOVICH, BANACH, MARCOTTE, HARDMAN, ARGIRIADI, GONNELLA, XIANG, LEONARD, CAMARRA, DIXON, YU, KIM, BREINLINGER AND GOEDKEN REGARDING TNF α PROJECT: IDEAS FOR COMPOUND, BINDING ASSAYS, ETC. (ARGIRIADI, 03/10/09)	ABT00975833			R			
PX 319	WO 92/11383 ISSUED TO ADAIR ET AL. ENTITLED, "RECOMBINANT ANTIBODIES SPECIFIC FOR TNF α ." (MARKS, 04/09/09)	ABT00033450-33509				X		06/12/09
PX 320	WO 91/09967 ISSUED TO ADAIR ET AL. ENTITLED, "HUMANISED ANTIBODIES." (MARKS, 04/09/09)	ABT00086954-87045				X		06/12/09
PX 323	ARTICLE ENTITLED, "HUMAN MONOCLONAL ANTIBODIES PRODUCED BY PRIMARY IN VITRO IMMUNIZATION OF PERIPHERAL BLOOD LYMPHOCYTES," AUTHORED BY BORREBAECK ET AL. AND PUBLISHED IN PROC. NATL. ACAD. SCI. USA, VOL. 85, PP. 3995-3999, JUNE 1988 IMMUNOLOGY. (MARKS, 04/09/09)	CCOR01792541-1792545				X		06/12/09
PX 324	ARTICLE ENTITLED, "MOLECULAR EVOLUTION OF PROTEINS OF FILAMENTOUS PHAGE," AUTHORED BY MARKS ET AL. AND PUBLISHED BY THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL. 267, NUMBER 23, AUGUST 15, 1992. (MARKS, 04/09/09)	CCOR01779872-1779877				X		06/12/09
PX 325	PUBLICATION BY MARKS ENTITLED, "CHAPTER 2 - HUMAN MONOCLONAL ANTIBODIES FROM V-GENE REPERTOIRES EXPRESSED ON BACTERIOPHAGE," PUBLISHED IN ANTIBODY ENGINEERING PP. 53-88. (MARKS, 04/09/09)	CCOR01792601-1792647				X		06/12/09
PX 326	WO 90/05144 ISSUED TO WINTER ET AL. ENTITLED, "SINGLE DOMAIN LIGANDS, RECEPTORS COMPRISING SAID LIGANDS, METHODS FOR THEIR PRODUCTION AND USE OF SAID LIGANDS AND RECEPTORS." (MARKS, 04/09/09)	ABT00260441-260537				X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 327	WO 92/01047 ISSUED TO MCCAFFERTY ET AL. ENTITLED, "METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS." (MARKS, 04/09/09)	ABT00260538-260749				X		06/12/09
PX 328	ADVERTISEMENT -- CAT ANTIBODY ENGINEERING BY THE INNOVATORS IN SCIENCE, VOL. 253, 26 JULY 1991. (MARKS, 04/09/09)	CCOR01792583-1792585			P, H, F			
PX 329	HUMIRA PRODUCT/PROCESS DESCRIPTION. (MARKS, 04/09/09)	ABT00315259-315307				X		06/12/09
PX 330	ARTICLE ENTITLED, "TRANSFECTOMAS PROVIDE NOVEL CHIMERIC ANTIBODIES" AUTHORED BY MORRISON AND PUBLISHED IN SCIENCE VOL. 229, NO. 4719, 20 SEPTEMBER 1985 (MARKS, 04/09/09)	CCOR01792666-1792675				X		06/12/09
PX 331	03/20/09 EXPERT REPORT OF ARTHUR J. STEINER. (STEINER 04/14/09)							
PX 332	WEB PROFILE OF ARTHUR J. STEINER. (STEINER 04/14/09)							
PX 333	RESULTS OF PATENT SEARCH FOR STEINER AS ASSISTANT EXAMINER. (STEINER 04/14/09)							
PX 334	RESULTS OF PATENT SEARCH FOR STEINER AS PRIMARY EXAMINER. (STEINER 04/14/09)							
PX 335	U.S. PATENT 7,071,232 ISSUED TO TAUB ENTITLED, "SMALL MOLECULES THAT INCREASE THE CONVERSION OF FOOD TO BODY WEIGHT." (STEINER 04/14/09)				R, F			
PX 336	TRANSACTION HISTORY FOR 09/256,763. (STEINER 04/14/09)				R, F			
PX 337	U.S. UTILITY PATENT APPLICATION FOR 6,166,086. (STEINER 04/14/09)				R			
PX 338	TRANSACTION HISTORY FOR 09/637,917. (STEINER 04/14/09)				R			
PX 339	U.S. UTILITY PATENT APPLICATION FOR 7,071,232. (STEINER 04/14/09)				R			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 340	U.S. PATENT 6,472,227 ISSUED TO ADAMCZYK ENTITLED, "BARBITUATE ASSAY, TRACERS, IMMUNOGENS, ANTIBODIES AND KIT." (STEINER 04/14/09)				R			
PX 341	TRANSACTION HISTORY FOR 06/870,671. (STEINER 04/14/09)				R			
PX 342	TRANSACTION HISTORY FOR 07/284,781. (STEINER 04/14/09)				R			
PX 343	TRANSACTION HISTORY FOR 07/524,195. (STEINER 04/14/09)				R			
PX 344	TRANSACTION HISTORY FOR 08/033,075. (STEINER 04/14/09)				R			
PX 345	FAMILY TREE FOR U.S. PATENT 6,090,382. (STEINER 04/14/09)				R			
PX 346	06/30/04 APPLICATION FOR EXTENSION OF PATENT TERM AND TRANSMITTAL LETTER FOR U.S. PATENT 6,090,382. (STEINER 04/14/09)				R			
PX 347	CONTINUITY DATA FOR 08/599,226. (STEINER 04/14/09)				R			
PX 348	TRANSACTION HISTORY FOR 10/302,356. (STEINER 04/14/09)				R			
PX 349	01/27/03 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDES SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES FOR 10/302,356. (STEINER 04/14/09)				R			
PX 350	03/27/03 RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDES SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES FOR 10/302,356. (STEINER 04/14/09)							
PX 351	04/16/03 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDES SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES FOR 10/302,356. (STEINER 04/14/09)							

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 352	06/16/03 RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDES SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES FOR 10/302,356. (STEINER 04/14/09)							
PX 353	03/21/05 OFFICE ACTION SUMMARY REGARDING 10/302,356. (STEINER 04/14/09)							
PX 354	09/21/05 TRANSMITTAL FORMS. (STEINER 04/14/09)							
PX 355	11/29/05 NOTICE OF ABANDONMENT OF 10/302,356. (STEINER 04/14/09)							
PX 356	TRANSACTION HISTORY FOR 09/801,185. (STEINER 04/14/09)							
PX 357	04/19/01 NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION FOR 09/801,185. (STEINER 04/14/09)							
PX 358	11/19/01 REQUEST FOR FIVE-MONTH EXTENSION OF TIME FOR 09/801,185. (STEINER 04/14/09)							
PX 359	11/19/01 PRELIMINARY AMENDMENT AND RESPONSE TO NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION FOR 09/801,185. (STEINER 04/14/09)							
PX 360	09/09/02 OFFICE ACTION SUMMARY FOR 09/801,185. (STEINER 04/14/09)							
PX 361	03/10/03 PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(A) FOR 09/801,185. (STEINER 04/14/09)							
PX 362	01/23/09 EXCERPT PAGES FROM THE DEPOSITION OF JOCHEN SALFELD. (STEINER 04/14/09)				Depo.			
PX 363	CERTIFIED COPY OF FILE HISTORY FOR APPLICATION 07/943,852. (STEINER 04/14/09)							

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 364	11/05/08 NOTICE OF DEPOSITION PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 30(B)(6). (POULOS, 04/23/09)					X		06/12/09
PX 365	04/06/09 EXPERT REPORT OF GERALD M. MURPHY, JR.				H			
PX 366	EXHIBIT 1 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – CV OF GREGORY P. ADAMS, PH.D.					X		06/12/09
PX 367	EXHIBIT 2 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – LIST OF MATERIALS CONSIDERED BY GREG ADAMS, PH.D.					X		06/12/09
PX 368	EXHIBIT 5 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – DEFENDANT ABBOTT LABORATORIES' OBJECTIONS AND RESPONSES TO PLAINTIFFS' FIRST SET OF REQUEST FOR ADMISSIONS [NOS. 1-12].					X		06/12/09
PX 369	EXHIBIT 8 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – 01/23/09 DEPOSITION TRANSCRIPT OF DR. IOCHEN G. SALFELD.				Depo.			
PX 370	EXHIBIT 9 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – GENERAL FLOW CHARTS AND OVERVIEW OF MANUFACTURING PROCESS.	ABT00074664-74869				X		06/12/09
PX 371	EXHIBIT 11 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – 10/21/08 DEPOSITION TRANSCRIPT OF JAMES D. MARKS.				Depo.			
PX 372	EXHIBIT 12 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – LAB NOTEBOOK NO. 8948.	CCOR01788994-1789228			A, H, R, P, F			
PX 373	EXHIBIT 13 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – 03/06/09 DEPOSITION TRANSCRIPT OF PAUL SAKORAFAS.				Depo.			

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 374	EXHIBIT 17 TO 03/20/09 EXPERT REPORT OF GREGORY P. ADAMS, PH.D. ON PATENT INFRINGEMENT – 02/24/09 DEPOSITION TRANSCRIPT OF ZEHRA KAYMAKALAN.				Depo.			
PX 375	02/23/05 ABBOTT PROFESSIONAL MARKETING RHEUMATOLOGY PLAN.	ABT00261072-261222			H, F	X		06/12/09
PX 376	2006 HUMIRA PROFESSIONAL MARKETING PLAN.	ABT00430384-430466			H, F	X		06/12/09
PX 377	MAY/JUNE 2007 ABBOTT 2008 STRATEGIC PLAN HUMIRA RHEUMATOLOGY.	ABT00433671-433773			H, F	X		06/12/09
PX 378	06/2007 HUMIRA DERMATOLOGY ATU MAY, 2007.	ABT00721277-721358			H, F	X		06/12/09
PX 379	07/25/07 ABBOTT FINAL PRESENTATION – HUMIRA GASTRO ATU – W2 JUNE 07.	ABT00721688-721806			H, F	X		06/12/09
PX 380	06/19/07 ABBOTT FINAL PRESENTATION – HUMIRA GASTRO ATU – WAVE 1 – FIELDDED MARCH-APRIL 2007.	ABT00721807-721848			H, F	X		06/12/09
PX 381	03/07 HUMIRA RHEUMATOLOGY ATU JANUARY 2007.	ABT00722729-722807			H, F	X		06/12/09
PX 382	06/07 HUMIRA RHEUMATOLOGY ATU Q2 2007.	ABT00722808-722912			H, F	X		06/12/09
PX 383	HUMIRA RHEUMATOLOGY ATU NOVEMBER 2007.	ABT00722913-723000			H, F	X		06/12/09
PX 384	06/04/07 DRAFT – HUMIRA 2008 RHEUM STRATEGIC PLAN – MAY/JUNE 2007.	ABT01007216-1007243				X		06/12/09
PX 385	01/03/07 DRAFT – RHEUMATOID ARTHRITIS MARKET LANDSCAPE & PATIENT EXPERIENCE OVERVIEW DECEMBER, 2006.	ABT01307039-1307193			H, F	X		06/12/09
PX 386	06/27/08 ABBOTT FINAL PRESENTATION – HUMIRA GASTRO ATU – MAY 08.	ABT01383090-1383210			H, F	X		06/12/09
PX 387	12/18/08 ABBOTT FINAL PRESENTATION – HUMIRA GASTRO ATU – OCT 08.	ABT01383211-1383278			H, F	X		06/12/09
PX 388	07/12/05 WAVE 6 – HUMIRA: RHEUMATOID ARTHRITIS MONTHLY TREATMENT SURVEY.	ABT01383325-1383385			H, F			
PX 389	HUMIRA RHEUMATOLOGY ATU JUNE 2008.	ABT01387505-1387584			H, F	X		06/12/09
PX 390	03/2007 HUMIRA DERMATOLOGY ATU JANUARY, 2007.	ABT00721205-721276			H, F	X		06/12/09
PX 391	2004 2.1 BIOLOGICS TARGETS TEAM DOCUMENT. (CONWAY. 04/15/09)	ABT00332668-332792			R, P, F, O	X		06/12/09

EX. NO.	DESCRIPTION	BATES NO.	Marked	Offered	Objection	Pre-admitted	Admitted	DATE
PX 392	2004 2.1 BIOLOGICS TARGETS TEAM DOCUMENT. (CONWAY, 04/15/09)	ABT00343349-343384			R, P, F, O	X		06/12/09
PX 393	12/08/04 BIOLOGICS TARGETS TEAM. (CONWAY, 04/15/09)	ABT00888914-888945			R, P, F, O	X		06/12/09
PX 394	12/14/05 EMAIL FROM CONWAY TO POPE, GOLLER, HALE AND YASGER REGARDING CENTOCOR'S CLAIMS. (CONWAY, 04/15/09)	ABT01394494				X		06/12/09
PX 395	CERTIFIED COPY OF FILE HISTORY FOR U.S. PATENT 7,070,775 ISSUED TO LE ET AL. ENTITLED, "RECOMBINANT A2-SPECIFIC TNF α SPECIFIC ANTIBODIES." (CONWAY, 04/15/09)	CCOR00000097-527				X		06/12/09
PX 396	04/02/09 DEFENDANTS' PRIVILEGE LOG. (CONWAY, 04/15/09)				O, R			
PX 397	04/14/09 LETTER WITH ATTACHMENT FROM MAJOR TO PEARSON REGARDING ABBOTT'S SLIGHTLY UPDATED PRIVILEGE LOG. (CONWAY, 04/15/09)				O, R			
PX 398	COPY OF FILE HISTORY FOR U.S. PATENT 6,090,382 ISSUED TO SALFELD ET AL. ENTITLED, "HUMAN ANTIBODIES THAT BIND HUMAN TNF α ." (CONWAY, 04/15/09)	ABT00033146-33419				X		06/12/09
PX 399	01/26/06 EMAIL STRING FROM MURTAZA TO SALFELD, IBRAGHIMOV, HSIEH, TRACEY, CONWAY, BACHMANN, YAN, GHAYUR, FUJIMORI, KAYMAKALAN AND OLSON REGARDING ALPHAV-BETA3. (CONWAY, 04/15/09)	ABT003332117-332121			R			
PX 400	06/10/05 EMAIL FROM HEYMAN TO POULOS, DEMPSEY AND SCODARI REGARDING DRAFT AGENDA JUNE 13 MEETING. (DEMPSEY, 04/17/09)	ABT00977709-977710			P, R, H, FRE 408			
PX 401	12/14/05 EMAIL FROM POULOS TO LIEPMANN, SZELA, MASON AND DEMPSEY REGARDING DECEMBER 13 MEETING - NEXT STEPS. (DEMPSEY, 04/17/09)	ABT01394683-1394685			P, R, FRE 408			
PX 402	03/06/07 EMAIL FROM POULOS TO LEBE REGARDING FEBRUARY HIGHLIGHTS. (DEMPSEY, 04/17/09)	ABT01395199-1395204			P, R, FRE 408			